STOCK TITAN

GILEAD SCIENCES (GILD) SEC Filings, Dec 2025-Jan 2026

GILD NASDAQ

Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.

Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.

Rhea-AI Summary

Gilead Sciences director Jeffrey Bluestone exercised non-qualified stock options for 5,000 shares of common stock at $67.4500 per share on January 20, 2026, then sold 5,000 shares at $123.5000 per share the same day under a Rule 10b5-1 trading plan adopted on February 13, 2025. After these transactions, he holds 8,920 shares of Gilead common stock directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
insider
-
Rhea-AI Summary

A holder filed a notice to sell 5,000 shares of the issuer’s common stock through Morgan Stanley Smith Barney, with an aggregate market value of $617,500 on NASDAQ.

The 5,000 shares are to be sold after being acquired the same day via a stock option exercise paid in cash. The issuer has 1,240,679,623 common shares outstanding. During the prior three months, the same seller, identified as Jeffrey Bluestone of Foster City, California, sold 5,000 common shares for gross proceeds of $625,400.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.00%
Tags
other
-
Rhea-AI Summary

Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported a small, pre-planned stock sale. On January 15, 2026, he sold 3,000 shares of Gilead common stock at a price of $124.31 per share. After this transaction, he continued to beneficially own 150,503 shares of the company’s common stock in direct ownership.

The sale was executed under a Rule 10b5-1 trading plan that was adopted on August 29, 2024, meaning the trade was scheduled in advance under a preset plan rather than being decided at the time of sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
insider
Rhea-AI Summary

Gilead Sciences Chief Commercial Officer Johanna Mercier reported a sale of company stock in an insider transaction. On January 15, 2026, she sold 3,000 shares of Gilead Sciences common stock at a price of $124.31 per share, reported under transaction code "S" for a sale. After this transaction, she beneficially owned 103,221 shares of Gilead common stock in direct ownership.

The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan, which was adopted on February 20, 2025. Such plans allow insiders to pre-arrange trades according to preset instructions, providing a structured way to sell shares over time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
insider
-
Rhea-AI Summary

Johanna Mercier has filed a Form 144 notice to sell 3,000 shares of common stock through Morgan Stanley Smith Barney on or about 01/15/2026 on the NASDAQ market. The planned sale has an aggregate market value of $372,930.00, and the issuer has 1,240,679,623 shares outstanding. The shares to be sold come from restricted stock and performance share awards acquired from the issuer in early 2024.

Over the past three months, Johanna Mercier has already sold 3,000 and 28,000 shares of common stock in separate transactions, with gross proceeds of $366,000.00 and $3,524,173.10, respectively. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
other
-
Rhea-AI Summary

An insider has filed a Rule 144 notice to sell 3,000 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC, with an aggregate market value of $372,930.00. The filing notes that there were 1,240,679,623 shares outstanding of this class, providing context for the size of the planned sale.

The shares to be sold were acquired on 01/24/2023 as performance shares from the issuer, with 3,000 securities acquired and deemed fully paid as of that date. The notice indicates an approximate sale date of 01/15/2026 on the NASDAQ exchange.

In the past three months, the person for whose account the securities are to be sold, Andrew Dickinson, has already sold 3,000 common shares on 12/15/2025 for gross proceeds of $366,000.00 and 2,500 common shares on 11/17/2025 for gross proceeds of $313,075.00. By signing, the seller represents that they do not know of undisclosed material adverse information about the issuer’s operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
other
Rhea-AI Summary

Gilead Sciences disclosed that its Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of the company’s common stock on December 15, 2025 at a price of $122 per share. Following this sale, he beneficially owns 153,503 shares, held directly. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
insider
-
Rhea-AI Summary

Gilead Sciences, Inc. reported an insider stock sale by its Chief Commercial Officer, Johanna Mercier. On 12/15/2025, Mercier sold 3,000 shares of Gilead common stock at $122 per share in a sale transaction coded "S".

After this sale, she beneficially owns 106,221 shares directly. The report notes that the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025, which allows executives to schedule trades in advance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
insider
-
Rhea-AI Summary

Gilead Sciences CEO Daniel P. O'Day reported insider stock activity involving restricted stock units linked to Gilead Sciences, Inc. common stock. On 12/10/2025, 10,426 restricted stock units were converted into 10,426 shares of common stock, increasing his directly held shares before a related disposition.

On the same date, 4,931 shares of common stock were disposed of at a price of $ 121.34 per share. After these transactions, O'Day directly owned 576,698 shares of Gilead common stock and 88,070 restricted stock units. Each restricted stock unit represents the right to receive one share, and the units follow a four-year vesting schedule in which 25% vest on the first anniversary of the grant date and the remaining balance vests 6.25% quarterly until fully vested.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
insider
Rhea-AI Summary

Gilead Sciences Chief Commercial Officer Johanna Mercier reported routine equity award activity involving restricted stock units and company shares. On 12/10/2025, 3,842 restricted stock units converted into an equal number of Gilead common shares. On the same date, 1,814 shares of common stock were disposed of in a transaction coded "F," indicating shares were withheld or used to cover tax obligations at a price of $121.34 per share.

After these transactions, Mercier directly beneficially owns 109,221 shares of Gilead common stock and 27,674 restricted stock units. Each restricted stock unit represents the contingent right to receive one share, and the units follow a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining units vesting 6.25% quarterly until fully vested.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
insider

FAQ

How many GILEAD SCIENCES (GILD) SEC filings are available on StockTitan?

StockTitan tracks 184 SEC filings for GILEAD SCIENCES (GILD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GILEAD SCIENCES (GILD)?

The most recent SEC filing for GILEAD SCIENCES (GILD) was filed on November 17, 2026.